Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
WASHINGTON Philip Morris International Inc should not be allowed to claim its iQOS electronic tobacco product is less risky than cigarettes, U.S. health advisers said on Thursday, dealing a blow to the company as it seeks to strengthen its portfolio of alternative nicotine devices. | Video
WASHINGTON Philip Morris International Inc told a U.S. advisory panel on Wednesday that it expects around 6 million smokers to switch completely to its iQOS electronic tobacco device if the company is allowed to claim it is less risky than cigarettes.
WASHINGTON, Jan 24 U.S. health advisers on Wednesday began to consider whether Philip Morris International Inc should be allowed to claim its novel electronic tobacco product is less harmful than cigarettes, potentially making it the first such device to carry a reduced risk claim.
WASHINGTON In a decision expected to test the Trump administration's approach to tobacco regulation, U.S. health advisers will vote this week on whether to allow Philip Morris International Inc to claim its novel iQOS tobacco device is less harmful than cigarettes.
WASHINGTON The U.S. government is seeking to further protect the "conscience and religious freedom" of health workers whose beliefs prevent them from carrying out abortions and other procedures, in an effort likely to please conservative Christian activists and other supporters of President Donald Trump. | Video
The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.
Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.
A proposal by the U.S. Food and Drug Administration to create a new fast-track path to market for medical devices may exceed its authority and require some creative reasoning to justify, legal experts said.
The U.S. Food and Drug Administration on Tuesday approved Spark Therapeutics Inc's treatment for a rare form of blindness, marking the first time the agency has approved a gene therapy for an inherited disease.
The U.S. Food and Drug Administration on Monday proposed creating a new fast track to market for certain medical devices and a potential reduction in the amount of safety data required for approval.